Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NGP 555 in healthy subjects
NCT02537938Phase 1Completed
- Sponsor
- NeuroGenetic Pharmaceuticals
- Start
- Jan 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing NGP 555 with Placebo (2 arms). Primary endpoint: Number of adverse events or safety outcomes. Started Jan 2016; status: completed.
02
Drugs
NGP 555
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02537938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537938.